Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.
News|Articles|May 11, 2026
4 Hematology Headlines You Missed in April 2026
Author(s)Alex Hillenbrand
Fact checked by: Victoria Johnson
Catch up on the hematology news and data you missed from April 2026.
Advertisement
Advertisement
April 2026 brought major developments in hematology, particularly in
Related to this article
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
The FDA approved asundexian with antiplatelet therapy after non-cardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.
Clinicians at ACAAI 2026 will see late-breaking HAE, anaphylaxis, urticaria, and food allergy data, plus exclusive expert interviews.
Mona Shahriari, MD, and Valerie D. Callender, MD, discuss trial diversity, better outcome measures, and how investigators can earn patient trust.
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study in > 1000 participants with highly chronic TRD.
In a UCB-funded network meta-analysis of 17 trials, bimekizumab ranked first on HiSCR50, HiSCR75, and IHS4-55 among HS drugs at Weeks 12 - 16.
The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.
Advertisement
Advertisement